Challenging the Biginelli scaffold to surpass the first line antitubercular drugs:

Mycobacterium tuberculosis / drug effects Antitubercular Agents / pharmacology Nucleoside-Phosphate Kinase / antagonists & inhibitors Structure-Activity Relationship Microbial Sensitivity Tests Molecular Structure Dose-Response Relationship, Drug Mice Models, Molecular Animals RAW 264.7 Cells Enzyme Inhibitors / pharmacology
Biginelli Mycobacterium tuberculosis thymidine monophosphate kinase Tetrahydropyrimidine antitubercular activity molecular dynamics simulation

Journal

Journal of enzyme inhibition and medicinal chemistry
ISSN: 1475-6374
Titre abrégé: J Enzyme Inhib Med Chem
Pays: England
ID NLM: 101150203

Informations de publication

Date de publication:
Dec 2024
Historique:
medline: 11 9 2024
pubmed: 11 9 2024
entrez: 11 9 2024
Statut: ppublish

Résumé

New Biginelli adducts were rationalised,

Identifiants

DOI: 10.1080/14756366.2024.2386668 PMID: 39258667
pubmed: 39258667
doi: 10.1080/14756366.2024.2386668
doi:

Substances chimiques

Antitubercular Agents 0
Nucleoside-Phosphate Kinase EC 2.7.4.4
dTMP kinase EC 2.7.4.9
Enzyme Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2386668

Auteurs

Mai S El-Shoukrofy (MS)

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
ORCID: 0000-0002-3016-5055

Amal Atta (A)

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.

Salwa Fahmy (S)

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.

Dharmarajan Sriram (D)

Medicinal Chemistry Research Laboratory, Pharmacy Group, Birla Institute of Technology and Science, Pilani, India.

Michael G Shehat (MG)

Department of Microbiology and Immunology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
ORCID: 0000-0002-0418-456X

Ibrahim M Labouta (IM)

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
ORCID: 0000-0001-7660-3287

Mona A Mahran (MA)

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
ORCID: 0000-0002-3456-941X

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Bâtonnets à Gram positif › Bâtonnets asporogènes à Gram positif › Bâtonnets asporogènes réguliers à Gram positif › Mycobacteriaceae › Mycobacterium › Mycobacterium tuberculosis › Challenging the Biginelli scaffold to surpass...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Antituberculeux › Challenging the Biginelli scaffold to surpass...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Transferases › Phosphotransferases › Phosphotransferases (Phosphate Group Acceptor) › Nucleoside phosphate kinase › Challenging the Biginelli scaffold to surpass...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Relation structure-activité › Challenging the Biginelli scaffold to surpass...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Tests de sensibilité microbienne › Challenging the Biginelli scaffold to surpass...
questionsmedicales.fr › Phénomènes chimiques › Structure moléculaire › Challenging the Biginelli scaffold to surpass...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes toxicologiques › Relation dose-effet des médicaments › Challenging the Biginelli scaffold to surpass...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Challenging the Biginelli scaffold to surpass...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles moléculaires › Challenging the Biginelli scaffold to surpass...
questionsmedicales.fr › Eucaryotes › Animaux › Challenging the Biginelli scaffold to surpass...
questionsmedicales.fr › Cellules › Cellules RAW 264.7 › Challenging the Biginelli scaffold to surpass...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Challenging the Biginelli scaffold to surpass...